Transmission of ceftazidime-avibactam-resistant Escherichia coli among pets, veterinarians and animal hospital environment
Ceftazidime-avibactam (CZA) is a recently approved combination synthetic β-lactamase inhibitor used in human clinical medicine. Cases of CZA resistance in humans have already been reported, but limited research has investigated CZA resistance in pets. This study explored the prevalence and transmiss...
Saved in:
Main Authors: | Hegen Dai (Author), Dongyan Shao (Author), Yu Song (Author), Qi An (Author), Zhenbiao Zhang (Author), Haixia Zhang (Author), Siyu Chen (Author), Congming Wu (Author), Jianzhong Shen (Author), Yanli Lyu (Author), Yang Wang (Author), Shizhen Ma (Author), Zhaofei Xia (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
by: Karoline Knudsen List, et al.
Published: (2022) -
Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012-2018
by: Gregory G. Stone, et al.
Published: (2022) -
Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024) -
Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021) -
Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022)